TG Therapeutics, Inc. (NASDAQ: TGTX) Stock Competitors & Peer Comparison
See TGTX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TGTX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TGTX | $52.03 | -2.80% | 8B | 17.88 | $2.91 | N/A |
| VRTX | $477.10 | -0.95% | 121.1B | 25.35 | $18.82 | N/A |
| REGN | $762.63 | +3.29% | 78.6B | 16.71 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $853.82 | -3.26% | 54.3B | 78.75 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.57 | -3.14% | 42.7B | -2.32 | -$4.15 | N/A |
| RVMD | $187.53 | -2.41% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $316.01 | -1.88% | 33.8B | 70.70 | $4.47 | N/A |
| ALNY | $205.52 | -28.30% | 27.4B | 37.02 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
TGTX vs VRTX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while VRTX trades at $477.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas VRTX's P/E ratio is 25.35. In terms of profitability, TGTX's ROE is +0.87%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, TGTX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
TGTX vs REGN Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while REGN trades at $762.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas REGN's P/E ratio is 16.71. In terms of profitability, TGTX's ROE is +0.87%, compared to REGN's ROE of +0.18%. Regarding short-term risk, TGTX is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
TGTX vs VRNA Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas VRNA's P/E ratio is -102.80. In terms of profitability, TGTX's ROE is +0.87%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, TGTX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
TGTX vs ARGX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ARGX trades at $853.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ARGX's P/E ratio is 78.75. In terms of profitability, TGTX's ROE is +0.87%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, TGTX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
TGTX vs SGEN Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas SGEN's P/E ratio is -57.19. In terms of profitability, TGTX's ROE is +0.87%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, TGTX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
TGTX vs RVMDW Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while RVMDW trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, TGTX's ROE is +0.87%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, TGTX is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
TGTX vs RVMD Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while RVMD trades at $187.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas RVMD's P/E ratio is -26.52. In terms of profitability, TGTX's ROE is +0.87%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, TGTX is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
TGTX vs ONC Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ONC trades at $316.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ONC's P/E ratio is 70.70. In terms of profitability, TGTX's ROE is +0.87%, compared to ONC's ROE of +0.12%. Regarding short-term risk, TGTX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
TGTX vs ALNY Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ALNY trades at $205.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ALNY's P/E ratio is 37.02. In terms of profitability, TGTX's ROE is +0.87%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, TGTX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
TGTX vs ROIV Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ROIV trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ROIV's P/E ratio is -34.86. In terms of profitability, TGTX's ROE is +0.87%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, TGTX is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
TGTX vs INCY Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while INCY trades at $119.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas INCY's P/E ratio is 16.06. In terms of profitability, TGTX's ROE is +0.87%, compared to INCY's ROE of +0.30%. Regarding short-term risk, TGTX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
TGTX vs BNTX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas BNTX's P/E ratio is -19.61. In terms of profitability, TGTX's ROE is +0.87%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, TGTX is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
TGTX vs UTHR Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while UTHR trades at $517.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas UTHR's P/E ratio is 19.10. In terms of profitability, TGTX's ROE is +0.87%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, TGTX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
TGTX vs MRNA Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while MRNA trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas MRNA's P/E ratio is -6.73. In terms of profitability, TGTX's ROE is +0.87%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, TGTX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
TGTX vs INSM Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while INSM trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas INSM's P/E ratio is -17.15. In terms of profitability, TGTX's ROE is +0.87%, compared to INSM's ROE of -1.30%. Regarding short-term risk, TGTX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
TGTX vs BGNE Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas BGNE's P/E ratio is -22.55. In terms of profitability, TGTX's ROE is +0.87%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, TGTX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
TGTX vs DNA-WT Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, TGTX's ROE is +0.87%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, TGTX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
TGTX vs GMAB Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas GMAB's P/E ratio is 20.77. In terms of profitability, TGTX's ROE is +0.87%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, TGTX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
TGTX vs NBIX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while NBIX trades at $166.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas NBIX's P/E ratio is 24.10. In terms of profitability, TGTX's ROE is +0.87%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, TGTX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
TGTX vs JAZZ Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while JAZZ trades at $252.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, TGTX's ROE is +0.87%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, TGTX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
TGTX vs BBIO Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while BBIO trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas BBIO's P/E ratio is -21.41. In terms of profitability, TGTX's ROE is +0.87%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, TGTX is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
TGTX vs ASND Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ASND trades at $243.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ASND's P/E ratio is -100.79. In terms of profitability, TGTX's ROE is +0.87%, compared to ASND's ROE of -56.42%. Regarding short-term risk, TGTX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
TGTX vs EXEL Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while EXEL trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas EXEL's P/E ratio is 15.88. In terms of profitability, TGTX's ROE is +0.87%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, TGTX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
TGTX vs KRTX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas KRTX's P/E ratio is -28.09. In terms of profitability, TGTX's ROE is +0.87%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, TGTX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
TGTX vs ARWR Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ARWR trades at $84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ARWR's P/E ratio is -39.37. In terms of profitability, TGTX's ROE is +0.87%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, TGTX is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
TGTX vs BMRN Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while BMRN trades at $60.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas BMRN's P/E ratio is 28.86. In terms of profitability, TGTX's ROE is +0.87%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, TGTX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
TGTX vs TECH Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas TECH's P/E ratio is 37.16. In terms of profitability, TGTX's ROE is +0.87%, compared to TECH's ROE of +0.05%. Regarding short-term risk, TGTX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
TGTX vs RNAM Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas RNAM's P/E ratio is -17.39. In terms of profitability, TGTX's ROE is +0.87%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, TGTX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
TGTX vs AXSM Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while AXSM trades at $217.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas AXSM's P/E ratio is -56.92. In terms of profitability, TGTX's ROE is +0.87%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, TGTX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check AXSM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
TGTX vs MDGL Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while MDGL trades at $467.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas MDGL's P/E ratio is -36.51. In terms of profitability, TGTX's ROE is +0.87%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, TGTX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check MDGL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
TGTX vs SMMT Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while SMMT trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas SMMT's P/E ratio is -8.14. In terms of profitability, TGTX's ROE is +0.87%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, TGTX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
TGTX vs KRYS Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while KRYS trades at $341.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas KRYS's P/E ratio is 45.60. In terms of profitability, TGTX's ROE is +0.87%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, TGTX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
TGTX vs HALO Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while HALO trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas HALO's P/E ratio is 17.87. In terms of profitability, TGTX's ROE is +0.87%, compared to HALO's ROE of +1.26%. Regarding short-term risk, TGTX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
TGTX vs CYTK Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while CYTK trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas CYTK's P/E ratio is -13.23. In terms of profitability, TGTX's ROE is +0.87%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, TGTX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
TGTX vs RXDX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas RXDX's P/E ratio is -56.47. In terms of profitability, TGTX's ROE is +0.87%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, TGTX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
TGTX vs ABVX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ABVX trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ABVX's P/E ratio is -65.48. In terms of profitability, TGTX's ROE is +0.87%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, TGTX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
TGTX vs NUVL Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas NUVL's P/E ratio is -21.79. In terms of profitability, TGTX's ROE is +0.87%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, TGTX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
TGTX vs CRNX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while CRNX trades at $83.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas CRNX's P/E ratio is -16.28. In terms of profitability, TGTX's ROE is +0.87%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, TGTX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
TGTX vs PTGX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while PTGX trades at $136.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas PTGX's P/E ratio is -75.49. In terms of profitability, TGTX's ROE is +0.87%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, TGTX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
TGTX vs IMGN Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas IMGN's P/E ratio is -111.55. In terms of profitability, TGTX's ROE is +0.87%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, TGTX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check IMGN's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
TGTX vs IONS Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while IONS trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas IONS's P/E ratio is -30.10. In terms of profitability, TGTX's ROE is +0.87%, compared to IONS's ROE of -1.11%. Regarding short-term risk, TGTX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
TGTX vs PRAX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while PRAX trades at $307.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas PRAX's P/E ratio is -23.02. In terms of profitability, TGTX's ROE is +0.87%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, TGTX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
TGTX vs SYRE Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while SYRE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas SYRE's P/E ratio is -47.27. In terms of profitability, TGTX's ROE is +0.87%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, TGTX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check SYRE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
TGTX vs KYMR Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while KYMR trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas KYMR's P/E ratio is -29.29. In terms of profitability, TGTX's ROE is +0.87%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, TGTX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check KYMR's competition here
Alkermes plc (NASDAQ: ALKS)
TGTX vs ALKS Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ALKS trades at $48.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ALKS's P/E ratio is 52.66. In terms of profitability, TGTX's ROE is +0.87%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, TGTX is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ALKS's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
TGTX vs BPMC Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas BPMC's P/E ratio is -51.58. In terms of profitability, TGTX's ROE is +0.87%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, TGTX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
TGTX vs APGE Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while APGE trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas APGE's P/E ratio is -30.97. In terms of profitability, TGTX's ROE is +0.87%, compared to APGE's ROE of -0.33%. Regarding short-term risk, TGTX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
TGTX vs CERE Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas CERE's P/E ratio is -16.47. In terms of profitability, TGTX's ROE is +0.87%, compared to CERE's ROE of -0.72%. Regarding short-term risk, TGTX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
TGTX vs IMVT Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while IMVT trades at $38.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas IMVT's P/E ratio is -14.46. In terms of profitability, TGTX's ROE is +0.87%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, TGTX is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
TGTX vs PCVX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while PCVX trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas PCVX's P/E ratio is -7.86. In terms of profitability, TGTX's ROE is +0.87%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, TGTX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
TGTX vs IBRX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas IBRX's P/E ratio is -8.44. In terms of profitability, TGTX's ROE is +0.87%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, TGTX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
TGTX vs MTSR Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas MTSR's P/E ratio is -23.58. In terms of profitability, TGTX's ROE is +0.87%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, TGTX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
TGTX vs MRUS Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas MRUS's P/E ratio is -17.05. In terms of profitability, TGTX's ROE is +0.87%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, TGTX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
TGTX vs RYTM Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while RYTM trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas RYTM's P/E ratio is -31.71. In terms of profitability, TGTX's ROE is +0.87%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, TGTX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
TGTX vs ACLX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ACLX's P/E ratio is -28.27. In terms of profitability, TGTX's ROE is +0.87%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, TGTX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
TGTX vs COGT Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while COGT trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas COGT's P/E ratio is -18.45. In terms of profitability, TGTX's ROE is +0.87%, compared to COGT's ROE of -0.83%. Regarding short-term risk, TGTX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
TGTX vs RETA Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas RETA's P/E ratio is -66.29. In terms of profitability, TGTX's ROE is +0.87%, compared to RETA's ROE of +0.47%. Regarding short-term risk, TGTX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
TGTX vs MIRM Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while MIRM trades at $105.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas MIRM's P/E ratio is -7.78. In terms of profitability, TGTX's ROE is +0.87%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, TGTX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
TGTX vs BLTE Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while BLTE trades at $158.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas BLTE's P/E ratio is -84.82. In terms of profitability, TGTX's ROE is +0.87%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, TGTX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
TGTX vs ERAS Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ERAS trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ERAS's P/E ratio is -19.51. In terms of profitability, TGTX's ROE is +0.87%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, TGTX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
TGTX vs CGON Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while CGON trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas CGON's P/E ratio is -30.55. In terms of profitability, TGTX's ROE is +0.87%, compared to CGON's ROE of -0.23%. Regarding short-term risk, TGTX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
TGTX vs CNTA Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas CNTA's P/E ratio is -22.63. In terms of profitability, TGTX's ROE is +0.87%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, TGTX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
TGTX vs XENE Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while XENE trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas XENE's P/E ratio is -13.33. In terms of profitability, TGTX's ROE is +0.87%, compared to XENE's ROE of -0.49%. Regarding short-term risk, TGTX is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
TGTX vs LGND Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while LGND trades at $287.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas LGND's P/E ratio is 34.48. In terms of profitability, TGTX's ROE is +0.87%, compared to LGND's ROE of +0.16%. Regarding short-term risk, TGTX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
TGTX vs SRRK Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while SRRK trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas SRRK's P/E ratio is -13.17. In terms of profitability, TGTX's ROE is +0.87%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, TGTX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check SRRK's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
TGTX vs PTCT Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while PTCT trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas PTCT's P/E ratio is -29.19. In terms of profitability, TGTX's ROE is +0.87%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, TGTX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
TGTX vs CDTX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas CDTX's P/E ratio is -19.77. In terms of profitability, TGTX's ROE is +0.87%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, TGTX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
TGTX vs ABCM Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, TGTX's ROE is +0.87%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, TGTX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
TGTX vs ISEE Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ISEE's P/E ratio is -22.44. In terms of profitability, TGTX's ROE is +0.87%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, TGTX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
TGTX vs APLS Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas APLS's P/E ratio is 38.35. In terms of profitability, TGTX's ROE is +0.87%, compared to APLS's ROE of +0.40%. Regarding short-term risk, TGTX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
TGTX vs TVTX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while TVTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas TVTX's P/E ratio is -254.05. In terms of profitability, TGTX's ROE is +0.87%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, TGTX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
TGTX vs TERN Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas TERN's P/E ratio is -51.41. In terms of profitability, TGTX's ROE is +0.87%, compared to TERN's ROE of -0.20%. Regarding short-term risk, TGTX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
TGTX vs DFTX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while DFTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas DFTX's P/E ratio is N/A. In terms of profitability, TGTX's ROE is +0.87%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, TGTX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check DFTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
TGTX vs DYN Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while DYN trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas DYN's P/E ratio is -7.82. In terms of profitability, TGTX's ROE is +0.87%, compared to DYN's ROE of -0.64%. Regarding short-term risk, TGTX is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check DYN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
TGTX vs CRSP Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while CRSP trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas CRSP's P/E ratio is -9.39. In terms of profitability, TGTX's ROE is +0.87%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, TGTX is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
TGTX vs FOLD Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas FOLD's P/E ratio is -161.00. In terms of profitability, TGTX's ROE is +0.87%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, TGTX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
TGTX vs AKRO Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas AKRO's P/E ratio is -14.57. In terms of profitability, TGTX's ROE is +0.87%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, TGTX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check AKRO's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
TGTX vs DNTH Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while DNTH trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas DNTH's P/E ratio is -25.89. In terms of profitability, TGTX's ROE is +0.87%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, TGTX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check DNTH's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
TGTX vs ALPN Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ALPN's P/E ratio is -101.52. In terms of profitability, TGTX's ROE is +0.87%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, TGTX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
TGTX vs ACAD Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ACAD trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ACAD's P/E ratio is 12.68. In terms of profitability, TGTX's ROE is +0.87%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, TGTX is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
TGTX vs CAI Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while CAI trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas CAI's P/E ratio is -86.19. In terms of profitability, TGTX's ROE is +0.87%, compared to CAI's ROE of +0.06%. Regarding short-term risk, TGTX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
TGTX vs MANE Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas MANE's P/E ratio is -33.36. In terms of profitability, TGTX's ROE is +0.87%, compared to MANE's ROE of -0.84%. Regarding short-term risk, TGTX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
TGTX vs OPT Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas OPT's P/E ratio is -1.52. In terms of profitability, TGTX's ROE is +0.87%, compared to OPT's ROE of +1.18%. Regarding short-term risk, TGTX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
TGTX vs PRTC Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas PRTC's P/E ratio is -3.78. In terms of profitability, TGTX's ROE is +0.87%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, TGTX is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check PRTC's competition here
Celcuity Inc. (NASDAQ: CELC)
TGTX vs CELC Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while CELC trades at $86.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas CELC's P/E ratio is -22.15. In terms of profitability, TGTX's ROE is +0.87%, compared to CELC's ROE of -2.45%. Regarding short-term risk, TGTX is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
TGTX vs EWTX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while EWTX trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas EWTX's P/E ratio is -23.15. In terms of profitability, TGTX's ROE is +0.87%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, TGTX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
TGTX vs MRTX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas MRTX's P/E ratio is -4.82. In terms of profitability, TGTX's ROE is +0.87%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, TGTX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
TGTX vs ELVN Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ELVN trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ELVN's P/E ratio is -32.82. In terms of profitability, TGTX's ROE is +0.87%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, TGTX is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
TGTX vs CPRX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas CPRX's P/E ratio is 12.30. In terms of profitability, TGTX's ROE is +0.87%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, TGTX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
TGTX vs RYZB Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas RYZB's P/E ratio is -57.86. In terms of profitability, TGTX's ROE is +0.87%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, TGTX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
TGTX vs CBAY Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas CBAY's P/E ratio is -32.81. In terms of profitability, TGTX's ROE is +0.87%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, TGTX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
TGTX vs VKTX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while VKTX trades at $31.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas VKTX's P/E ratio is -7.67. In terms of profitability, TGTX's ROE is +0.87%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, TGTX is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
TGTX vs DNLI Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas DNLI's P/E ratio is -7.99. In terms of profitability, TGTX's ROE is +0.87%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, TGTX is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
TGTX vs ORKA Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ORKA trades at $96.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ORKA's P/E ratio is -49.75. In terms of profitability, TGTX's ROE is +0.87%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, TGTX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ORKA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
TGTX vs ADPT Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ADPT trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ADPT's P/E ratio is -41.80. In terms of profitability, TGTX's ROE is +0.87%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, TGTX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ADPT's competition here
Alumis Inc. (NASDAQ: ALMS)
TGTX vs ALMS Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ALMS trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ALMS's P/E ratio is -7.39. In terms of profitability, TGTX's ROE is +0.87%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, TGTX is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ALMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
TGTX vs RCUS Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while RCUS trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas RCUS's P/E ratio is -8.66. In terms of profitability, TGTX's ROE is +0.87%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, TGTX is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
TGTX vs SWTX Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas SWTX's P/E ratio is -13.78. In terms of profitability, TGTX's ROE is +0.87%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, TGTX is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for TGTX.Check SWTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
TGTX vs ARQT Comparison August 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TGTX stands at 8B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, TGTX is priced at $52.03 on the NASDAQ, while ARQT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TGTX currently has a P/E ratio of 17.88, whereas ARQT's P/E ratio is -933.00. In terms of profitability, TGTX's ROE is +0.87%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, TGTX is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for TGTX.Check ARQT's competition here